The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
P & D??? Yawn!
£1.10 may indeed be the answer
roughly doubled on pure speculation
Ian12, never seen a p&d on here, never any volume. Post placing where did we get to? £1.40 first stop.
Can't sell 20k now, so illiquid as always.
7ark me, that escalated quickly, only managed another 500 at 91 then it ran away
I waited 15 minutes today to buy on order.
Couldn’t get a quote which is pretty bad on the MM
Where did the P&D take place? I missed it.
It's just the usual P&D.
Question is: without great contract news, how high?
And here’s the link to the TB article in the Indian press Barnacle ;)
https://health-economictimes-indiatimes-com.cdn.ampproject.org/c/s/health.economictimes.indiatimes.com/amp/news/industry/feedback-wins-ihw-digital-health-2024-gold-award-in-india/107449329
It’s surely implausible that having won such a relevant award that Bleepa should consequently fail to be a part of the planned TB screening programme given the acknowledgment that digital technology has to be at the heart of it.
Modri wants to eliminate TB from India by the end of 2025, a very ambitious target. He’d better get a move on then!
The partnership that Feedback has with Qure.ai is also worth noting, both for opportunities in India and the UK. From September 2021:
“We are delighted to be working with Qure.ai; …this is only the beginning to forging a pathway for a new global regime of diagnostic testing and screening. The combination of Qure.ai’s AI reporting capabilities through Bleepa’s instant and secure communications platform has the potential to provide timely, efficient and cost-effective care across a number of clinical settings.
“We are particularly excited to be working on screening for TB and to help deliver this to even the remotest of locations. We have the potential here to build true access to healthcare for all in India. Although we are looking at India initially, Qure.ai are a great partner and their technologies hold just as much benefit here in the UK and we are excited to explore a number of opportunities for the technologies within the NHS and UK private market. ”
“We are delighted to be working with Qure.ai; …this is only the beginning to forging a pathway for a new global regime of diagnostic testing and screening. The combination of Qure.ai’s AI reporting capabilities through Bleepa’s instant and secure communications platform has the potential to provide timely, efficient and cost-effective care across a number of clinical settings.
“We are particularly excited to be working on screening for TB and to help deliver this to even the remotest of locations. We have the potential here to build true access to healthcare for all in India. Although we are looking at India initially, Qure.ai are a great partner and their technologies hold just as much benefit here in the UK and we are excited to explore a number of opportunities for the technologies within the NHS and UK private market. ”
FEEDBACK WINS IHW GOLD AWARD - SUPPORTING TB SCREENING PROGRAMMES IN RURAL COMMUNITIES, Jan 2024
Bleepa uses local mobile networks to securely push X-rays, acquired in rural settings, to a dedicated cloud environment where they can be processed by AI to assist interpretation. Specialists can review the images using Bleepa’s in-app clinical grade image viewer and chat directly with the care team in the rural setting to reach the correct management plan for the patient, supported by the AI-generated report.
Bleepa connects with Qure.ai’s AI platform so the images can be processed and interpreted, returning the results within a matter of minutes. This helps the radiologist to triage the scan and flag any abnormalities which would indicate a TB diagnosis.
Since the start of the project in March 2022 nearly 2,000 patients have been screened at the hospital, with 19.6% of scans coming back as indicating positive for signs of TB.
All looking very rosy, just a shame the mms don't make a market. Still can't get a quote to buy anything at all, not even £100s worth!
Just to continue on from the same theme of yesterday. The TB opportunity (if realised) is HUGE for Feedback. There isn’t really an adequate word to describe it tbh.
To give an illustration (going on information previously provided by TO in 2021) the cost (in 2021) for the Indian government to provide an individual screening per patient was £20.
Tom stated that Feedback could provide the Bleepa offering for £2 per patient giving an EBITDA return of 80% margin! That would leave 90% for other partnership providers (such as Quere.ai and AWS to take their slice.
In terms of patient numbers to be screened, India is huge, so we are talking many millions per state. One state could provide in excess of £15m revenue (if population 7.5m x £2 for a random example)
The numbers are truly staggering and it’s no exaggeration to say that IF they are chosen to participate in the screening as a digital partner, and we know the trial was clearly successful this would 20, 30, 50 bag from here.
Digital Personal Data Protection Act 2023: Impact On Indian Healthcare Industry
‘The Digital Personal Data Protection Act, 2023 (DPDP Act) is a new law regulating personal data processing in India. It aims to protect the privacy rights of individuals and create a framework for data governance and accountability. The DPDP Act will significantly impact the Indian healthcare industry, which is still in its early stages of digital evolution.’
https://sujeetkatiyar.medium.com/digital-personal-data-protection-act-2023-impact-on-indian-healthcare-industry-f8e52321dc14
Yes it is. The key to all this was the (imo) inspired appointment of Rohit Singh. This guy worked for the UK India Business Council for I think over ten years. Can you imagine the network of connections he built over that period? If you check out his LinkedIn profile you will see he is highly respected and well known in Indian business circles. Note the recent awards. As Tom pointed out in the recent webinar the ‘Jury’ which made the decision on the Digital Healthcare Award was made up of Indian government officials and big hitters in Indian business. All the type of influential decision makers you want to be noticed by. The best sales and marketing pitch Bleepa could have had!
Rohit also gave a talk at the same conference which was stated in the Key highlights as ‘Expert session on Digital innovation in clinical communication comply with Data Protection Act 2023 and other Use cases.’
What more can I say?
Yes it is. The key to all this was the (imo) inspired appointment of Rohit Singh. This guy worked for the UK India Business Council for I think over ten years. Can you imagine the network of connections he built over that period? If you check out his LinkedIn profile you will see he is highly respected and well known in Indian business circles. Note the recent awards. As Tom pointed out in the recent webinar the ‘Jury’ which made the decision on the Digital Healthcare Award was made up of Indian government officials and big hitters in Indian business. All the type of influential decision makers you want to be noticed by. The best sales and marketing pitch Bleepa could have had!
Rohit also gave a talk at the same conference which was stated in the Key highlights as ‘Expert session on Digital innovation in clinical communication comply with Data Protection Act 2023 and other Use cases.’
What more can I say?
Coffee - yes indeed. Human beings eh? No matter their background can be remarkably resistant to change. They get comfortable with what they have and seemingly less concerned with patients data security than their own ‘convenience’. One strongly suspects they will have to be dragged screaming into change. So be it!
India looking very tasty!
Dibs, strange that these medical professionals aren't aware of their wider industry surroundings?
Complaining that they will be stopped from sending grainy/blurry xray pics and not being aware of a superior product ?
‘ India implementing largest digital programme for TB surveillance, says official’
Read more at:
https://health.economictimes.indiatimes.com/news/industry/india-implementing-largest-digital-programme-for-tb-surveillance-says-official/107899554
I suppose it’s a mere coincidence that Feedback were awarded a Gold Award for Digital Innovation in Rural Healthcare in India (for their TB screening) at pretty much the same time that the news about a digital TB screening programme filters out.
https://health-economictimes-indiatimes-com.cdn.ampproject.org/c/s/health.economictimes.indiatimes.com/amp/news/industry/feedback-wins-ihw-digital-health-2024-gold-award-in-india/107449329
WhatsApp use is endemic in the NHS. What if there were an easy to use alternative for clinicians to use?
https://www.htworld.co.uk/news/digital-health/patient-care-will-suffer-if-new-laws-end-whatsapp-use-in-nhs-doctors-fear-nhs24/?amp=1
Dibs,
The UK private trials with MIB run 11 hospitals specialising in Xrays, India starter for 10, can see they are getting in at grass roots level and it should then move up as news spreads and cost savings and patient turn around times are noticed.
Salute, time for a beer and
It might...
History here shows that, when the sp rises, it flies
There is one hell of a good story here, and (even before we find out how it actually plays out), that might well be enough for serious gains
13 trades - that's busy compared to recent history!
52 Week High 179.50
Can we please have some news before April 1st.
GLA
Good find Dibs. - India has the ability to dwarf the NHS plus they're slightly more forward thinking and proactive around making changes. Join the dots indeed.
Jolly... 87p might seem cheap soon!
And Earl (plus all of your other aliases) well done, even you (or should that be they) have to be right sometimes!
Further to my last post checking out Shelby’s latest investor presentation in February.
Under the Multi Speciality heading (they run 10 hospitals) the following quote:
‘Adopting and leveraging technology to bring better medical outcomes and patient reach’
Hmmm I wonder who could help there? Join the dots.